>
Camurus AB logo

CAMX - Camurus AB Share Price

SEK204 -1.0  -0.5%

Last Trade - 11:40am

Sector
Healthcare
Size
Mid Cap
Market Cap £953.3m
Enterprise Value £915.9m
Revenue £28.8m
Position in Universe 335th / 1829
Bullish
Bearish
Unlock CAMX Revenue
Momentum
Relative Strength (%)
1m -3.91%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -13.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
154.8 113.7 54.3 49.3 105.6 336 999.8 1,079 +16.8%
-12.1
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, CamurusAB revenues increased from SEK105.6M to SEK336M. Net lossdecreased 42% to SEK167.3M. Revenues reflect an increase indemand for the Company's products and services due tofavorable market conditions. Basic Earnings per Shareexcluding Extraordinary Items increased from -SEK6.23 to-SEK3.18.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for CAMX
Graphical History

Revenue

CAMX Revenue Unlock CAMX Revenue

Net Income

CAMX Net Income Unlock CAMX Revenue

Normalised EPS

CAMX Normalised EPS Unlock CAMX Revenue

PE Ratio Range

CAMX PE Ratio Range Unlock CAMX Revenue

Dividend Yield Range

CAMX Dividend Yield Range Unlock CAMX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
CAMX EPS Forecasts Unlock CAMX Revenue
Profile Summary

Camurus AB is a Sweden-based research and development based pharmaceutical company with a focus on the development and commercialization of specialty medicines, providing patients suffering from serious and chronic disease, such as opioid dependence, pain, cancer, acromegaly, and neuroendocrine tumors. The Company has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since December 3, 2015
No. of Shareholders: n/a
No. of Employees: 134
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 54,233,773
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CAMX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CAMX
Upcoming Events for CAMX
Thursday 6th May, 2021
Q1 2021 Camurus AB Earnings Release
Thursday 6th May, 2021
Q1 2021 Camurus AB Earnings Call
Frequently Asked Questions for Camurus AB
What is the Camurus AB share price?

As of 11:40am, shares in Camurus AB are trading at SEK204, giving the company a market capitalisation of £953.3m. This share price information is delayed by 15 minutes.

How has the Camurus AB share price performed this year?

Shares in Camurus AB are currently trading at SEK204 and the price has moved by 0.105k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Camurus AB price has moved by 55.35% over the past year.

What are the analyst and broker recommendations for Camurus AB?

Of the analysts with advisory recommendations for Camurus AB, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Camurus AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Camurus AB next release its financial results?

Camurus AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Camurus AB dividend yield?

Camurus AB does not currently pay a dividend.

Does Camurus AB pay a dividend?

Camurus AB does not currently pay a dividend.

When does Camurus AB next pay dividends?

Camurus AB does not currently pay a dividend.

How do I buy Camurus AB shares?

To buy shares in Camurus AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Camurus AB?

Shares in Camurus AB are currently trading at SEK204, giving the company a market capitalisation of £953.3m.

Where are Camurus AB shares listed? Where are Camurus AB shares listed?

Here are the trading details for Camurus AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: CAMX
What kind of share is Camurus AB?

Based on an overall assessment of its quality, value and momentum, Camurus AB is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Camurus AB share price forecast 2021?

Shares in Camurus AB are currently priced at SEK204. At that level they are trading at 24.63% discount to the analyst consensus target price of 0.00.

Analysts covering Camurus AB currently have a consensus Earnings Per Share (EPS) forecast of 4.28 for the next financial year.

How can I tell whether the Camurus AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Camurus AB. Over the past six months, the relative strength of its shares against the market has been -4.53%. At the current price of SEK204, shares in Camurus AB are trading at 8.69% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Camurus AB PE Ratio?

We were not able to find PE ratio data for Camurus AB.

Who are the key directors of Camurus AB?

Camurus AB's management team is headed by:

Fredrik Tiberg - PRE
Fredrik Joabsson - VBD
Torsten Malmstrom - CTO
Eva Pinotti-Lindqvist - CFO
Agneta Svedberg - VPR
Per Wallstrom - CHM
Per-Anders Abrahamsson - IND
Marianne Dicander Alexandersson - IND
Martin Jonsson - IND
Richard Jameson - OTH
Behshad Sheldon - IND
Mark Never - IND
Urban Paulsson - VPR
Annette Mattsson - VPR
Who are the major shareholders of Camurus AB?

Here are the top five shareholders of Camurus AB based on the size of their shareholding:

Sandberg (Per) Individual Investor
Percentage owned: 40.57% (22.0m shares)
Fjärde AP-Fonden Pension Fund
Percentage owned: 6.14% (3.33m shares)
Max Mitteregger Kapitalförvaltning AB Hedge Fund
Percentage owned: 4.77% (2.59m shares)
Avanza Bank Holding AB Corporation
Percentage owned: 3.45% (1.87m shares)
Tiberg (Fredrik) Individual Investor
Percentage owned: 3.05% (1.65m shares)
Similar to CAMX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.